The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.50
Bid: 98.00
Ask: 99.00
Change: -1.00 (-1.01%)
Spread: 1.00 (1.02%)
Open: 99.50
High: 99.00
Low: 98.50
Prev. Close: 99.50
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Jan 2020 14:53

RNS Number : 2155A
Diaceutics PLC
17 January 2020
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

DIACEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

15 JANUARY 2020

6. Date on which issuer notified (DD/MM/YYYY):

17 JANUARY 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.0729

10.0729

69,583,077

Position of previous notification (if

applicable)

9.8285

9.8285

 

 

 

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJQTGV64

7,009,000

10.0729

 

SUBTOTAL 8. A

7,009,000

10.0729

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Canaccord Genuity Group Inc.

10.0729

10.0729

Canaccord Genuity Wealth Group Holdings Limited

10.0729

10.0729

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

10.0729

10.0729

Canaccord Genuity Wealth Group Limited

10.0729

10.0729

Hargreave Hale Ltd

10.0729

10.0729

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

BLACKPOOL, ENGLAND

Date of completion

17 JANUARY 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLZDLFFBFLEBBL
Date   Source Headline
13th Mar 202310:12 amRNSFurther update regarding Silicon Valley Bank
13th Mar 20237:30 amRNSSuspension - Diaceutics PLC
13th Mar 20237:00 amRNSUpdate regarding Silicon Valley Bank
1st Mar 20231:57 pmRNSPDMR Shareholding/Share Incentive Plan
30th Jan 20235:11 pmRNSPDMR Shareholding/Share Incentive Plan
26th Jan 20237:00 amRNSUSD 7m enterprise engagements for data services
26th Jan 20237:00 amRNSTrading Statement and Strategy Update
3rd Jan 20237:00 amRNSPDMR Shareholding/Share Incentive Plan
29th Nov 20227:00 amRNSChange of Auditor
29th Nov 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Nov 20227:00 amRNSSub-optimal testing impacts on cancer patients
31st Oct 20222:20 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20225:03 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20227:00 amRNSPurchase of Shares and PDMR Shareholding
27th Sep 20227:00 amRNSHalf-year Report
12th Sep 202212:38 pmRNSPDMR Shareholding/Share Incentive Plan
8th Sep 20227:00 amRNSNotice of Results and Presentations
8th Aug 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
26th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Jul 20225:45 pmRNSPDMR Shareholding/Share Incentive Plan
13th Jun 20227:00 amRNSMulti-year contract with top five global pharma
7th Jun 20227:00 amRNSNew AI and ML Capabilities Enhance DXRX Platform
31st May 202212:12 pmRNSPDMR Shareholding/Share Incentive Plan
27th May 20224:31 pmRNSShare Options and PDMR Shareholdings
26th May 20223:00 pmRNSResult of AGM
11th May 20222:34 pmRNSPDMR Shareholding/Share Incentive Plan
9th May 20224:37 pmRNSExercise of Warrant & Total Voting Rights
5th May 20227:00 amRNSContract Win
29th Apr 20225:22 pmRNSPDMR Shareholding/Share Incentive Plan
28th Apr 20222:09 pmRNSNotice of AGM and Posting of Annual Report
7th Apr 20227:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
6th Apr 20221:13 pmRNSPDMR Shareholding/Share Incentive Plan
5th Apr 20223:49 pmRNSConversion of Convertible Loan Notes & TVR
1st Apr 20227:00 amRNSIssue of Share Options / PDMR Shareholdings
31st Mar 20225:38 pmRNSPDMR Shareholding/Share Incentive Plan
22nd Mar 20222:43 pmRNSFinal Results
22nd Mar 20227:00 amRNSNotice of 2021 Full Year Results
18th Mar 20222:09 pmRNSConfirmation of Directorate Change
16th Mar 20225:49 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSApproval by CMS for enhanced data access
2nd Mar 20225:37 pmRNSPDMR Shareholding/Share Incentive Plan
21st Feb 20227:00 amRNSInvestor Presentation
14th Feb 20226:26 pmRNSPDMR Shareholding/Share Incentive Plan
14th Feb 20227:00 amRNSContract with leading life sciences company
4th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Jan 20227:01 amRNSDirectorate Change
11th Jan 20227:00 amRNSTrading Update and Notice of Results
4th Jan 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
14th Dec 20217:00 amRNSContract Win
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.